Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets

Pathology Research and Practice

Volumn 204, Issue 10, 2008, Pages 695-706

  Wei, Shi ^a   Siegal, Gene P ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bone; Interleukins; Osteoclast; Osteolysis; TNF

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 15; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; PARVOVIRUS VECTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETROVIRUS VECTOR; RITUXIMAB; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BONE ATROPHY; BONE DISEASE; CELL ACTIVATION; CELL ACTIVITY; CELL MATURATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG TARGETING; GENE THERAPY; HUMAN; LUNG CANCER; MEDICAL RESEARCH; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOTHERAPY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE RESORPTION; GENE THERAPY; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; OSTEOCLASTS; OSTEOLYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 52049084316     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.07.002     Document Type: Review

References (112)

1. Adriaansen J., Vervoordeldonk M.J., and Tak P.P. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology, Oxford 45 (2006) 656-668
2. Andreakos E., Foxwell B., and Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol. Rev. 202 (2004) 250-265
3. Arend W.P. The mode of action of cytokine inhibitors. J. Rheumatol. Suppl. 65 (2002) 16-21
4. Berenbaum F., Humbert L., Bereziat G., and Thirion S. Concomitant recruitment of ERK1/2 and p38 MAPK signalling pathway is required for activation of cytoplasmic phospholipase A2 via ATP in articular chondrocytes. J. Biol. Chem. 278 (2003) 13680-13687
5. Beyaert R., Cuenda A., Vanden Berghe W., et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. Embo J. 15 (1996) 1914-1923
6. Body J.J., Greipp P., Coleman R.E., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
7. Breuil V., and Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73 4 (2006) 349-354
8. Cella M., Buonsanti C., Strader C., Kondo T., Salmaggi A., and Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J. Exp. Med. 198 (2003) 645-651
9. Childs L.M., Paschalis E.P., Xing L., et al. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J. Bone Miner. Res. 17 (2002) 192-199
10. Dayer J.M. Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?. J. Rheumatol. Suppl. 65 (2002) 10-15
11. Dinarello C.A. Interleukin-1. Cytokine Growth Factor Rev. 8 (1997) 253-265
12. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13 (1999) 2412-2424
13. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2572-2581
14. Emery P. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin. Invest. Drugs 12 (2003) 673-681
15. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54 (2006) 1390-1400
16. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 19 (2001) 163-196
17. Franzoso G., Carlson L., Xing L., et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482-3496
18. Furst D.E., Breedveld F.C., Kalden J.R., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum. Dis. 65 (2006) iii2-iii15
19. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353 (2005) 1114-1123
20. Goldblatt F., and Isenberg D.A. New therapies for rheumatoid arthritis. Clin. Exp. Immunol. 140 (2005) 195-204
21. Goldblatt F., and Isenberg D.A. New therapies for systemic lupus erythematosus. Clin. Exp. Immunol. 140 (2005) 205-212
22. Goldring S.R., Jasty M., Roelke M.S., Rourke C.M., Bringhurst F.R., and Harris W.H. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis Rheum. 29 (1986) 836-842
23. Goya J.A., Paez H.A., and Mandalunis P.M. Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats. J. Periodontol. 77 (2006) 1-6
24. Gravallese E.M., Manning C., Tsay A., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43 (2000) 250-258
25. Gravallese E.M. Bone destruction in arthritis. Ann. Rheum. Dis. 61 (2002) ii84-ii86
26. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266 (1994) 443-448
27. Harms J.F., Welch D.R., Samant R.S., et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis 21 (2004) 119-128
28. Harris W.H. The problem is osteolysis. Clin. Orthop. Relat. Res. 311 (1995) 46-53
29. Herlaar E., and Brown Z. p38 MAPK signaling cascades in inflammatory disease. Mol. Med. Today 5 (1999) 439-447
30. Hershey C.L., and Fisher D.E. Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone 34 (2004) 689-696
31. Hofbauer L.C., and Heufelder A.E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79 (2001) 243-253
32. Hogan P.G., Chen L., Nardone J., and Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 17 (2003) 2205-2232
33. Huk O.L., Zukor D.J., Antoniou J., and Petit A. Effect of pamidronate on the stimulation of macrophage TNF-alpha release by ultra-high-molecular-weight polyethylene particles: a role for apoptosis. J. Orthop. Res. 21 (2003) 81-87
34. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3 (1997) 1285-1289
35. Jimi E., Nakamura I., Duong L.T., et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247 (1999) 84-93
36. Jorgensen C., Noel D., Apparailly F., and Sany J. Stem cells for repair of cartilage and bone: the next challenge in osteoarthritis and rheumatoid arthritis. Ann. Rheum. Dis. 60 (2001) 305-309
37. Kaiser J. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science 299 (2003) 495
38. Kim N., Takami M., Rho J., Josien R., and Choi Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 195 (2002) 201-209
39. Kim N., Kadono Y., Takami M., et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202 (2005) 589-595
40. Kitaura H., Sands M.S., Aya K., et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. J. Immunol. 173 (2004) 4838-4846
41. Kitaura H., Zhou P., Kim H.J., Novack D.V., Ross F.P., and Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115 (2005) 3418-3427
42. Koga T., Inui M., Inoue K., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428 (2004) 758-763
43. Kong Y.Y., Feige U., Sarosi I., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
44. Koreny T., Tunyogi-Csapo M., Gal I., Vermes C., Jacobs J.J., and Glant T.T. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum. 54 (2006) 3221-3232
45. Kotake S., Udagawa N., Hakoda M., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44 (2001) 1003-1012
46. Kremer J.M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52 (2005) 2263-2271
47. Kyburz D., Rethage J., Seibl R., et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum. 48 (2003) 642-650
48. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
49. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., and Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 (2000) 1481-1488
50. Lark M.W., Stroup G.B., Dodds R.A., et al. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. J. Bone Miner. Res. 16 (2001) 319-327
51. Lark M.W., Stroup G.B., James I.E., et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30 (2002) 746-753
52. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41 (1998) 778-799
53. Lee J.C., Laydon J.T., McDonnell P.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
54. Lee S.K., Kalinowski J.F., Jastrzebski S.L., Puddington L., and Lorenzo J.A. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology 144 (2003) 3524-3531
55. Lee S.K., and Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140 (1999) 3552-3561
56. Lerner U.H. Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis. J. Dent. Res. 85 (2006) 596-607
57. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97 (2000) 1566-1571
58. Maini R.N., Taylor P.C., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54 (2006) 2817-2829
59. Matsumoto M., Kogawa M., Wada S., et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 279 (2004) 45969-45979
60. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354 (2006) 821-831
61. Medicherla S., Ma J.Y., Mangadu R., et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J. Pharmacol. Exp. Ther. 318 (2006) 132-141
62. Miyazawa K., Mori A., and Okudaira H. Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by glucocorticoids. J. Biochem. (Tokyo) 124 (1998) 1130-1137
63. Moller B., and Villiger P.M. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin. Immunopathol. 27 (2006) 391-408
64. Moreland L.W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46 (2002) 1470-1479
65. Nakajima A. Application of cellular gene therapy for rheumatoid arthritis. Mod. Rheumatol. 16 (2006) 269-275
66. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis. (2007)
67. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2 (2006) 619-626
68. Nixon R., Bansback N., and Brennan A. The Efficacy of Inhibiting Tumour Necrosis Factor {alpha} and Interleukin 1 in Patients with Rheumatoid Arthritis: A Meta-analysis and Adjusted Indirect Comparisons (2007), Rheumatology, Oxford
69. Ochi S., Shinohara M., Sato K., et al. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc. Natl. Acad. Sci. USA 104 (2007) 11394-11399
70. Paccani S.R., Boncristiano M., Ulivieri C., D'Elios M.M., Del Prete G., and Baldari C.T. Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J. Biol. Chem. 277 (2002) 1509-1513
71. Peifer C., Wagner G., and Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 6 (2006) 113-149
72. Pihlstrom B.L., Michalowicz B.S., and Johnson N.W. Periodontal diseases. Lancet 366 (2005) 1809-1820
73. Quinn J.M., Horwood N.J., Elliott J., Gillespie M.T., and Martin T.J. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J. Bone Miner. Res. 15 (2000) 1459-1466
74. Raper S.E., Yudkoff M., Chirmule N., et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 13 (2002) 163-175
75. Raper S.E., Chirmule N., Lee F.S., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80 (2003) 148-158
76. Redlich K., Hayer S., Ricci R., et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 110 (2002) 1419-1427
77. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., and Schwarz E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111 (2003) 821-831
78. Robbins P.D., Evans C.H., and Chernajovsky Y. Gene therapy for arthritis. Gene Ther. 10 (2003) 902-911
79. Romas E., Gillespie M.T., and Martin T.J. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30 (2002) 340-346
80. Schett G., Tohidast-Akrad M., Smolen J.S., et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43 (2000) 2501-2512
81. Schieven G.L. The biology of p38 kinase: a central role in inflammation. Curr. Top. Med. Chem. 5 (2005) 921-928
82. Seales E.C., Micoli K.J., and McDonald J.M. Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. J. Cell. Biochem. 97 (2006) 45-55
83. Seibl R., Birchler T., Loeliger S., et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. 162 (2003) 1221-1227
84. Shakespeare W.C., Metcalf III C.A., Wang Y., et al. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr. Opin. Drug Discov. Dev. 6 (2003) 729-741
85. Sharma S.M., Bronisz A., Hu R., et al. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J. Biol. Chem. 282 (2007) 15921-15929
86. Shipman C.M., and Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63 (2003) 912-916
87. Shu G., Yamamoto K., and Nagashima M. Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts. Mod Rheumatol 16 (2006) 343-349
88. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
89. Smolen J.S., Aletaha M., Koeller D., Weisman M.H., and Emery P. New therapies for treatment of rheumatoid arthritis. Lancet (2007)
90. Suzuki M., Tetsuka T., Yoshida S., et al. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts. FEBS Lett. 465 (2000) 23-27
91. Sweeney S.E., and Firestein G.S. Mitogen activated protein kinase inhibitors: where are we now and where are we going?. Ann. Rheum. Dis. 65 (2006) iii83-iiii8
92. Takayanagi H., Kim S., Matsuo K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416 (2002) 7422224-7422229
93. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
94. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it?. Am. J. Pathol. 170 (2007) 427-435
95. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4 (2003) 638-649
96. Tondravi M.M., McKercher S.R., Anderson K., et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 396 (1997) 81-84
97. Toraldo G., Roggia C., Qian W.P., Pacific R., and Weitzmann M.N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. USA 100 (2003) 125-130
98. van Vollenhoven R.F., and Klareskog L. The treatment of rheumatoid arthritis: getting better all the time?. Arthritis Rheum. 52 (2005) 991-994
99. Vanags D., Williams B., Johnson B., et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 368 (2006) 855-863
100. Visentin L., Dodds R.A., Valente M., et al. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J. Clin. Invest. 106 (2000) 309-318
101. Wagner G., and Laufer S. Small molecular anti-cytokine agents. Med. Res. Rev. 26 (2006) 1-62
102. Wei S., Teitelbaum S.L., Wang M.W., and Ross F.P. Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 142 (2001) 1290-1295
103. Wei S., Wang M.W., Teitelbaum S.L., and Ross F.P. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J. Biol. Chem. 277 (2002) 6622-6630
104. Wei S., Kitaura H., Zhou P., Ross F.P., and Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115 (2005) 282-290
105. Wei S., and Siegal G.P. p38 MAPK as a potential therapeutic target for inflammatory osteolysis. Adv. Anat. Pathol. 14 (2007) 42-45
106. Wilkinson J.M., Wilson A.G., Stockley I., et al. Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty. J. Bone Miner. Res. 18 (2003) 1995-2001
107. Winzen R., Kracht M., Ritter B., et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. Embo J. 18 (1999) 4969-4980
108. Wu X., Ahn E.Y., McKenna M.A., Yeo H., and McDonald J.M. Fas binding to calmodulin regulates apoptosis in osteoclasts. J. Biol. Chem. 280 (2005) 29964-29970
109. Yoshida H., Hayashi S., Kunisada T., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345 (1990) 442-444
110. Zou W., Kitaura H., Reeve J., et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell. Biol. 176 (2007) 877-888
111. Zwerina J., Hayer S., Tohidast-Akrad M., et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50 (2004) 277-290
112. Zwerina J., Hayer S., Redlich K., et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum. 54 (2006) 463-472